.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Johnson and Johnson
Moodys
Cerilliant
Chinese Patent Office
US Army
Accenture
Federal Trade Commission
Farmers Insurance
Fuji

Generated: September 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 9,174,975 protect, and when does it expire?


Patent ► Subscribe protects LATUDA and is included in one NDA. There has been one Paragraph IV challenge on Latuda.

Protection for LATUDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ten patent family members in seven countries.

Summary for Patent: ► Subscribe

Title:Remedy for integration dysfunction syndrome
Abstract: The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without being accompanied by extrapyramidal symptoms, which comprises orally administering as an active compound (1R,2S,3R,4S)--N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylme- thyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) at a daily dose of 5 mg to 120 mg once a day to a patient with schizophrenia, and a therapeutic agent to be used in the method.
Inventor(s): Nakamura; Mitsutaka (Osaka, JP), Ogasa; Masaaki (Osaka, JP), Sami; Shunsuke (Osaka, JP)
Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD (Osaka, JP)
Application Number:10/525,021
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-003Dec 7, 2011RXYesNo► Subscribe► SubscribeY
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-001Oct 28, 2010RXYesYes► Subscribe► SubscribeY
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-005Jul 12, 2013RXYesNo► Subscribe► SubscribeY
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-002Oct 28, 2010RXYesNo► Subscribe► SubscribeY
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-004Apr 26, 2012RXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

PCT Information
PCT FiledAugust 20, 2003PCT Application Number:PCT/JP03/10490
PCT Publication Date:March 04, 2004PCT Publication Number: WO2004/017973

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria431147► Subscribe
JapanWO2004017973► Subscribe
Spain2326078► Subscribe
European Patent Office2295061► Subscribe
European Patent Office1944030► Subscribe
European Patent Office1535616► Subscribe
Germany60327634► Subscribe
Australia2003257589► Subscribe
Japan4745661► Subscribe
World Intellectual Property Organization (WIPO)2004017973► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Medtronic
Novartis
AstraZeneca
Fish and Richardson
Cerilliant
Queensland Health
Covington
Citi
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot